Table 2 Clinical characteristics of patients (N = 122)
|  | Cohort (N = 122) | Groups(%) | P | |
|---|---|---|---|---|
COPD (N = 61) | Non-COPD (N = 61) | |||
Age | Â | Â | Â | 0.230 |
median | 66 | 67 | 66 | Â |
range | 45–89 | 50–83 | 45–89 |  |
Sex | Â | Â | Â | 0.680 |
Male | 116(95.1) | 59(96.7) | 57(93.4) | Â |
Female | 6(4.9) | 2(3.3) | 4(6.6) | Â |
Smoking history | Â | Â | Â | 0.073 |
Never-smokers | 36(29.5) | 13(21.3) | 23(37.7) | Â |
Ever-smokers | 86(70.5) | 48(78.7) | 38(62.3) | Â |
Histology | Â | Â | Â | 0.053 |
Adenocarcinoma | 48(39.4) | 19(31.1) | 29(47.5) | Â |
Squamous | 67(54.9) | 40(65.6) | 27(44.3) | Â |
Others | 7(5.7) | 2(3.3) | 5(8.2) | Â |
ECOG performance status | Â | Â | Â | 0.752 |
0–1 | 120(98.4) | 60(98.4) | 60(98.4) |  |
2–3 | 2(1.6) | 1(1.6) | 1(1.6) |  |
Genetic profile | Â | Â | Â | 0.037 |
EGFR | 4(3.3) | 1(1.6) | 3(4.9) | Â |
KRAS | 7(5.7) | 1(1.6) | 6(9.8) | Â |
Others | 3(2.5) | 1(1.6) | 2(3.3) | Â |
Negative | 36(29.5) | 14(23.0) | 22(36.1) | Â |
NA | 72(59.0) | 44(72.1) | 27(44.3) | Â |
Fibrosis score | Â | Â | Â | 0.638 |
0 | 100(82.0) | 49(80.3) | 51(83.6) | Â |
≥1 | 22(18.0) | 12(19.7) | 10(16.4) |  |
Emphysema score | Â | Â | Â | 0.003 |
0 | 75(62.0) | 29(47.5) | 46(75.4) | Â |
≥ 1 | 47(38.0) | 32(52.5) | 15(24.6) |  |
Baseline spirometry | Â | Â | Â | 0.642 |
DLco% predicted* | 69.9(16.8) | 65.9(15.2) | 73.5(17.4) | Â |
irAE | Â | Â | Â | 0.211 |
No | 90(73.8) | 41(67.2) | 49(80.3) | Â |
CIP | 19(15.6) | 11(18.0) | 8(13.1) | Â |
Other irAE | 13(10.7) | 9(14.8) | 4(6.6) | Â |
Treatment line | Â | Â | Â | 0.847 |
Adjuvant | 21(17.2) | 11(18.0) | 10(16.4) | Â |
First-line | 77(63.1) | 38(62.3) | 39(63.9) | Â |
Second-line | 16(13.1) | 7(11.5) | 9(14.8) | Â |
Subsequent-line | 8(6.6) | 5(8.2) | 3(4.9) | Â |